Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease
about
Side effects of a dopamine agonist therapy for Parkinson's disease: a mini-review of clinical pharmacologyExtracellular matrix molecules: potential targets in pharmacotherapy.The non-ergot derived dopamine agonist quinagolide in prevention of early ovarian hyperstimulation syndrome in IVF patients: a randomized, double-blind, placebo-controlled trial.Health-related quality of life in Parkinson disease: correlation between Health Utilities Index III and Unified Parkinson's Disease Rating Scale (UPDRS) in U.S. male veteransDrug-induced valvulopathy: an update.Serotonin receptors and heart valve disease--it was meant 2B.Early prediction of long-term response to cabergoline in patients with macroprolactinomasContinuous drug delivery in Parkinson's disease.Pramipexole for the treatment of early Parkinson's disease.Medical management of Parkinson's disease: focus on neuroprotectionLong-acting versus standard non-ergot dopamine agonists in Parkinson's disease: a meta-analysis of randomized controlled trials.Pituitary surgery for small prolactinomas as an alternative to treatment with dopamine agonists.Aortic valve cyclic stretch causes increased remodeling activity and enhanced serotonin receptor responsivenessTrends in inpatient antiparkinson drug use in the USA, 2001-2012.Role and clinical utility of pramipexole extended release in the treatment of early Parkinson's disease.Parkinson's disease between internal medicine and neurologyNational Trends of Antiparkinsonism Treatment in Taiwan: 2004-2011.Non-Ergot Dopamine Agonists Do Not Increase the Risk of Heart Failure in Parkinson's Disease Patients: A Meta-Analysis of Randomized Controlled TrialsAcute pergolide exposure stiffens engineered valve interstitial cell tissues and reduces contractility in vitro.Motor and nonmotor complications in Parkinson's disease: an argument for continuous drug delivery?Current status of symptomatic medical therapy in Parkinson's diseaseA review of ropinirole prolonged release in Parkinson's disease.Cardiac surgery in a patient with retroperitoneal fibrosis and heart valvulopathy, both due to pergolide medication for Parkinson's disease.Consensus guideline for the diagnosis and treatment of aromatic l-amino acid decarboxylase (AADC) deficiency.Cabergoline therapy for prolactinomas: is valvular heart disease a real safety concern?Pramipexole extended-release (once-daily formulation) for the treatment of Parkinson's disease.In vitro safety pharmacology profiling: what else beyond hERG?Pharmacokinetic evaluation of pramipexole.Sleep-related movement disorders.Treatment for dystonia in childhood.Rotigotine transdermal patch for the treatment of Parkinson's Disease.Serotonin paracrine signaling in tissue fibrosisSummary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease.Management of medically refractory prolactinoma.Dopamine receptor agonists for Parkinson's disease.Pharmacotherapy for restless legs syndrome.Safety overview of FDA-approved medications for the treatment of the motor symptoms of Parkinson's disease.Dopamine agonists in prevention of ovarian hyperstimulation syndrome.Therapeutic strategies to prevent and manage dyskinesias in Parkinson's disease.Risks of Cardiac Valve Regurgitation and Heart Failure Associated with Ergot- and Non-Ergot-Derived Dopamine Agonist Use in Patients with Parkinson's Disease: A Systematic Review of Observational Studies.
P2860
Q26738349-633F0464-B974-4C92-BC83-396954EED1C2Q33694487-7CB6E6E1-32A9-46B8-A921-D66254D52075Q33731989-9315221F-3A77-419B-BFC3-921EDD833315Q34128695-9864B898-E374-425C-A62D-D8B38597A834Q34131760-C22E390F-A58A-488F-8B84-F7518C43C252Q34173511-C7016F07-7816-42CF-A5C2-8EAAF316B683Q34318860-FAE6F6F2-5E0E-4132-8AFD-15E1F78C58C3Q34390800-0366BF2D-5CB0-48AE-9A20-0B945EB1F381Q34630735-802595DC-72CB-4F30-B4EA-DB60546CE1D4Q35092165-85BD9824-DF7F-43C3-BD90-30A7EA675338Q35109436-E252C873-FD60-460D-B86A-8F2436FF1725Q35137687-8403BDD4-EDF6-4DD3-94C9-1317034022EBQ35250865-99BE5F65-8A63-49A3-B0BE-E9834E5924AEQ35847512-122E6388-F1E9-45A3-88CC-A5E17EF72A05Q35885133-81CCA324-58C7-4641-816F-F0AD4B055490Q36464243-5021DF18-234B-44D3-8ED5-94FE5A7D7C6AQ36644129-157A2D18-98B2-4A37-B90F-042ABC418662Q36856977-8AC87751-D69E-41F8-9917-AF21493D2F40Q36993985-008BF958-A1E8-4B0B-9803-5685C2278A09Q37115650-23CF58CD-2C51-4054-B3F6-A79A5A5A6160Q37131229-BFC35445-F742-4BB0-AE7C-6A94EC0A8C15Q37199938-69B3933F-E6CF-4961-90B4-A5B04DECC5FEQ37428207-317D9E67-C512-4AAC-92CB-BE3397A30BF6Q37591499-655D118D-BA55-45EA-A4A3-4ABF0081A33CQ37656282-4EAA389B-5E81-4D48-AB18-F951BCE3B2ADQ37776519-3775FC64-9A62-4570-A3B2-90308E3D0CD4Q37855844-AA9BC170-833B-4EBC-9DC0-1F992983F93FQ37926588-FB07DE51-701B-4BB3-8008-4C9040E136F9Q37971861-A8B3CC1C-1EA5-45E4-966C-270BC228B856Q37979912-982BBFA4-07F1-447D-BD67-088FA9009F71Q37982789-E63A90D0-5862-4FAF-AE15-2DDEC67DB589Q38049023-CD271633-4614-44F7-A5DB-80220CCA5219Q38070888-BB16D534-B112-457D-A842-07C749BDEB95Q38154516-2FADBE13-0C29-4C5B-9206-CF558CFDE608Q38169202-482EADD7-75CA-46A3-AD12-CE2DACF06059Q38205513-2348AD1E-407F-455B-96FC-DD2E2DA0E8F4Q38223072-BF756BE2-CC55-4210-B38C-E5813C2CFE93Q38237098-3054A43B-92A1-465A-85CD-8AC8063865F2Q38284574-0111F791-1B0C-4E8A-8A23-B31A94460A4AQ38639264-8176E56D-CA5A-43C9-B5E3-6384D03609A3
P2860
Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease
description
2007 nî lūn-bûn
@nan
2007 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease
@ast
Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease
@en
Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease
@nl
type
label
Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease
@ast
Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease
@en
Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease
@nl
prefLabel
Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease
@ast
Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease
@en
Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease
@nl
P3181
P1433
P1476
Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease
@en
P3181
P356
10.1016/S1474-4422(07)70218-1
P407
P577
2007-09-01T00:00:00Z